Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Pelthos Therapeutics Inc.AMEX: PTHS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $27.52M rose 10909.2% year over year, ahead of the +9047.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 52.7% from the prior quarter. Over 3 fiscal years it compounded at +203.5% a year.

Context

  • Financing cash flow amounted to 269.9% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10909.2% holds above the trailing-twelve-month pace of +9047.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27.52M+52.7% QoQ
Last fiscal yearDec 2025
$45.34M+630.1% YoY
LTMMar 2026
$72.61M+9047.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10909.2%——
1 year+630.1%——
3-year CAGR+203.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
45.34M USD
Year-over-year change
+630.1%
3-year CAGR
+203.5%

Financing Cash Flow vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 financing cash flow of $72.61M is the largest of the 4 companies compared; the peer median is $10.99M.
  • Its year-over-year change of +9047.0% is the highest of 4, against a peer median of +70.2%.
  • Financing cash flow amounts to 262.1% of revenue for PTHS.
PTHS Competitors Peer median
Financing Cash Flow for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTHSPelthos Therapeutics Inc.LTM Mar 2026$72.61M +9047.0%+203.5%262.1%
CINGCingulate Inc.LTM Mar 2026$36.15M +58.2%+48.8%—
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$10.99M +70.2%+310.6%—
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$9.4M +927.8%+26.1%—
Peer median (excluding PTHS) $10.99M+70.2%+48.8%—

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.46M)(7.38M)(7.96M)(43.32M)
Depreciation & Amortization0002.36M
Deferred Income Tax0000
Stock-Based Compensation110.15K1.73M1.8M0
Change in Working Capital640.86K2.05M34.63K(6.07M)
Accounts Receivables00(45.79K)(8.81M)
Inventory0001.78M
Accounts Payables413.6K1.63M1.18M1.36M
Other Working Capital227.26K424.07K(1.1M)(395K)
Other Non-Cash Items140.43K2.62M328.93K24.44M
Operating Cash Flow(1.57M)(981.03K)(5.79M)(22.59M)
Capital Expenditures000(99K)
Acquisitions (Net)000(5.14M)
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow000(5.24M)
Debt Repayment400K766.94K321.43K17.75M
Common Stock Issued0255.41K6.05M27.59M
Common Stock Repurchased00(166.51K)0
Dividends Paid0000
Other Financing Activities1.22M000
Financing Cash Flow1.62M1.02M6.21M45.34M
Effect of Forex Changes000(443)
Net Change in Cash55.07K41.32K417.05K17.51M
Free Cash Flow(1.57M)(981.03K)(5.79M)(22.69M)

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.